Enzyvant Therapeutics, Inc.
http://www.enzyvant.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Enzyvant Therapeutics, Inc.
What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
Regenerative Medicine Comes Of Age – In The Age Of COVID-19
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.
Dainippon Lays Out R&D Table Ahead Of Latuda Challenges
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Enzyvant Sciences, Ltd.